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Abstract
Background: Post-polio syndrome (PPS) is a condition that affects polio survivors years after recovery from an
initial acute infection by the Poliomyelitis virus. Most often, patients who suffered from polio start to experience
gradual new weakening in muscles, a gradual decrease in the size of muscles (muscle atrophy) and fatigue years
after the acute illness. L-citrulline is known to change muscular metabolism synthesis by raising nitric oxide (NO)
levels and increasing protein synthesis. This investigator-initiated, randomised, placebo-controlled, double-blind, trial
aims to demonstrate that L-citrulline positively influences muscle function and increases muscular energy
production in patients with PPS.
Methods/design: Thirty ambulant PPS patients will be recruited in Switzerland. Patients will be randomly allocated
to one of the two arms of the study (placebo:verum 1:1). After a 24-week run-in phase to observe natural disease
history and progression, participants will be treated either with L-citrulline or placebo for 24 weeks. The primary
endpoint is change in the 6-min Walking Distance Test. Secondary endpoints will include motor function measure,
quantitative muscle force, quantitative muscle magnetic resonance imaging and magnetic resonance spectroscopy
and serum biomarker laboratory analysis
Discussion: The aim of this phase IIa trial is to determine if treatment with L-citrulline shows a positive effect on
clinical function and paraclinical biomarkers in PPS. If treatment with L-citrulline shows positive effects, this might
represent a cost-efficient symptomatic therapy for PPS patients.
Trial registration: ClinicalTrial.gov, ID: NCT02801071. Registered on 6 June 2016.
Keywords: L-citrulline, Post-polio syndrome, Clinical trial, Quantitative MRI
Background
Poliomyelitis and post-polio syndrome (PPS)
Poliomyelitis is an infectious viral disease that can strike
at any age and affects the nervous system, resulting in
paralysis with muscle spasms and, in some cases, acute
encephalitis [1]. To date, most regions in the world are
certified polio free. However, poliomyelitis is still
endemic in two countries worldwide (Afghanistan and
Pakistan) with 74 reported cases in 2015 [2].
PPS is a condition that affects polio survivors years after
recovery from an initial acute infection by the Poliomyel-
itis virus. Most often, patients affected by polio start to
experience gradual new weakening in muscles which were
previously infected by the original polio infection [1].
The most common symptoms include slowly progres-
sive muscle weakness, fatigue (both generalised and
muscular) and a gradual decrease in muscle size (muscle
atrophy). The diagnosis of PPS relies nearly entirely on
clinical information. Physicians diagnose PPS after
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completing a comprehensive medical history and phys-
ical examination, and by excluding other disorders that
could explain the symptoms [3].
The exact incidence and prevalence of PPS is unknown.
Due to the large number of polio survivors, in 2004
250,000 patients with PPS were estimated in Europe, 20
million worldwide [4]. Ragonese et al. showed in 2005 a
prevalence rate for PPS of 31% (women more than men)
in patients affected by poliomyelitis [5].
The aetiology and pathogenesis of PPS are unclear. It
has been hypothesised that the new weakness of PPS
appears to be related to the degeneration of individual
nerve terminals in the motor units. The usage of these
recovered but overly extended motor units for years
overstresses the neurons which, over time, lose their
ability to maintain the increased work demands. This
results in slow deterioration of the neurons, leading to
reduced muscle strength [6, 7].
This hypothesis explains why PPS occurs after a delay
and has a slow and progressive course. There are
currently no effective pharmaceutical or rehabilitative
treatments that can stop the deterioration or reverse the
deficits caused by the syndrome itself [8].
L-citrulline
L-citrulline (CIT) is a nonessential amino acid, not
involved in protein synthesis. However, CIT plays a cen-
tral part in cellular metabolism. CIT is produced but not
metabolised in the gastrointestinal tract. More than 80%
of the citrulline produced by the gastrointestinal tract
appears to be taken up by the kidneys [9, 10]. CIT is
then converted to L-arginine in the renal proximal tu-
bules (via the enzymes arginosuccinate synthase and
arginosuccinate lyase) [9]. As a precursor of L-arginine,
CIT is transformed into nitric oxide (NO) by nitric oxide
synthase (NOS). El-Hattab et al. demonstrated that the
intake of CIT in MELAS (mitochondrial encephalomy-
opathy, lactic acidosis, and stroke-like episodes) patients
showed a substantially higher increase of L-arginine and
NO plasma concentrations than did the same dose of L-
arginine [11]. Both CIT and L-arginine support NO
synthesis in a variety of tissues, including muscle tissue.
Osowska et al. reported that with a CIT-enriched diet,
protein synthesis improved and, therefore, the protein
mass in the muscle could be increased [12]. NO triggers
mitochondrial biogenesis and enhances coupled respir-
ation and adenosintriphosphate (ATP) production. This
process is mediated via a cGMP (guanosine 3’,5’-mono-
phosphate)-dependent signalling pathway that activates
the expression of peroxisome proliferator-activated
receptor-γ coactivator 1α (PGC-1α), which is a master
regulator of mitochondrial biosynthesis [13].
Therefore, CIT supplementation results in reduced
fatigue and improved endurance for both aerobic and
anaerobic prolonged exercise. It seems to interact with
ATP production (in a beneficial manner) by increasing
the efficiency of energy production [14].
Single oral doses of CIT of up to 15 g are tolerated
without any side effects in contrast to equivalent oral
doses of L-arginine, where osmotic diarrhoea has been
observed [15]. The same observations may be reported
in our own studies (data not yet published) in which
CIT (doses of up to 15 g/d) was administered to patients
with Becker muscular dystrophy and Duchenne muscu-
lar dystrophy.
Unpublished results showed beneficial effects of CIT
on muscle function and fatigue in muscular dystrophies.
In both pathways, the stimulation of skeletal muscle pro-
tein syntheses via ATP production and mitochondrial
biosynthesis stimulation could be potentially useful in
other chronic neuromuscular disorders of neurogenic
origin such as PPS.
Methods/design
Study design
The study is an investigator-initiated, randomised,
placebo-controlled, double-blind, efficacy phase IIa trial
and is conducted over a time period of 48 weeks. We plan
to enrol 30 ambulant PPS patients aged older than
18 years. Recommendations for Interventional Trials
(SPIRIT) Checklist on which the study protocol is based is
presented as Additional file 1. A (SPIRIT) figure, showing
the planned visit and examination schedule is presented in
Fig. 2.
Inclusion criteria
In order to participate, patients are required to meet the
following criteria:
be ambulant patients aged 18 years and above at the
time of screening and able to walk 150 m in the 6-min
Walking Distance Test (6MWD); women of child-
bearing potential must be willing to use a contraceptive
during the study; there must be prior paralytic poliomy-
elitis with evidence of motor neuron loss. This is con-
firmed by history of the acute paralytic illness, signs of
residual muscle weakness and atrophy on neuromuscu-
lar examination, and signs of motor neuron loss.
A period of partial or complete functional recovery
after acute poliomyelitis, followed by an interval (usually
15 years or more) of stable neuromuscular function is
required and a slowly progressive and persistent new
muscle weakness or decreased endurance, with or with-
out generalised fatigue, muscle atrophy or muscle and
joint pain must be demonstrable. Symptoms must have
persisted for at least 1 year. Patients with other neuro-
muscular, medical and skeletal abnormalities causing the
symptoms are excluded.
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Exclusion criteria
Excluded are patients those who have previously
(3 months or less) or concomitantly participated in any
other therapeutic trial; the use of CIT or L-arginine
within the last 3 months; a known individual hypersensi-
tivity to CIT; a known or suspected malignancy; any
other chronic disease or clinically relevant limitation of
renal, hepatic or cardiac function at the discretion of the
investigator; pregnant or breast-feeding women and
patients with severe renal failure (calculated glomerular
filtration rate <30 ml/min).
Randomisation and blinding
Patients who meet the study admission criteria are en-
rolled in the study and a single subject identification
number will be assigned. Patients are allocated to the
two study groups, CIT or placebo, in a 1:1 ratio. The
trial is double blind, with both patients as well as the
investigators assessing outcomes blinded to treatment
allocation. Dropouts after visit 3 (week 24) will not be
replaced.
Intervention
All patients will undergo a 6-month observational (un-
treated) period to observe the natural history of their
condition. Afterwards, they will be randomised into a
verum or a placebo (1:1) group. All patients randomised
to the active compound receive a daily dose of 15 g CIT
(Hänseler AG, Herisau, Switzerland) separated in three
doses per day (3 × 5 g). The patients randomised to the
placebo group will receive matching placebo (sachets
look like verum but contain mannitol). Treatment is
given for a period of 24 weeks. At baseline (visit 2), week
24 (visit 3) as well as at the end of the study (visit 5),
clinical measures, laboratory and magnetic resonance
imaging (MRI) measures will be performed. This in-
cludes the 6MWD, the Motor Function Measurement
(MFM) scale, quantitative motor tests (QMT), motor
function assessment using quantitative thigh muscle
MRI, and magnetic resonance (MR) spectroscopy and
laboratory blood analysis. Furthermore, assessments
concerning quality of life and impairments concerning
daily activities are done with standardised questionnaires
(SIPP – Self-reported Impairments in Persons with late
effects of Polio, IBM-FRS – Inclusion Body Myositis
Functional Rating Scale; WHOQOL – The WHO Qual-
ity of Life – BREF Questionnaire). A flow chart showing
the study design is provided in Fig. 1.
To compare results of quantitative muscle MRI (It-
erative Decomposition of water and fat with Echo
Asymmetry and Least-squares estimation-Carr-Purcell-
Meiboom-Gill (IDEAL-CPMG) with T2 and lipid quan-
titation and dynamic 31P-MR spectroscopy), motor
function and serum markers of muscle necrosis, oxida-
tive and nitrosative stress with an age- and gender-
correlated group of people, up to 20 subjects not
suffering from neuromuscular disorders will be in-
cluded into a healthy control group. In this population,
the 6MWD, MFM scale, QMT, quantitative MRI and
MR spectroscopy and a blood test will be performed at
a single time point.
Study procedure
At screening (visit 1, day −1), patients are informed
about preclinical data, alternative treatments, risks and
possible benefits of the study. Further, written informed
consent is obtained. After signing the Informed Consent
Form, inclusion and exclusion criteria are verified. If the
criteria are fulfilled, the patient will be enrolled in the
study. During the screening visit, the following proce-
dures are performed: 6MWD; vital signs; physical exam-
ination; MFM scale. After screening, four visits will be
scheduled at baseline (week 0, visit 2), week 24 (visit 3),
week 36 (visit 4) and week 48 (visit 5, end of study).
During visit 2 (week 0, baseline), the following proce-
dures are performed: check inclusion/exclusion criteria;
Fig. 1 Flow chart showing the study design
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vital signs; physical examination; self-report question-
naires; muscle MRI; adverse events; blood draw (labora-
tory analysis) and urine pregnancy test in women of child-
bearing potential. If the patient still qualifies for the study,
they will be definitively enrolled in the study. Two weeks
after screening, self-report questionnaires are filled in a
second time by patients to evaluate the questionnaires for
test-retest reliability. During visit 3 (week 24), the follow-
ing procedures will be performed: 6MWD; vital signs;
physical examination; self-report questionnaires; MFM
scale; QMT; muscle MRI; adverse events; blood draw (la-
boratory analysis) and urine pregnancy test in women of
child-bearing potential. If the patient still qualifies for the
study, they will be randomised and receive the study
medication or placebo accordingly. During visit 4 (week
36), the following procedures are performed: 6MWD; vital
signs; physical examination; MFM scale; QMT adverse
events; blood draw (laboratory analysis); dispensing of
study medication; collection of boxes with sachets of used
study medication for compliance control. During the last
visit (visit 5, week 48, end of study), the following
procedures are performed: 6MWD; vital signs; physical
examination; self-report questionnaires; MFM scale;
QMT; muscle MRI; adverse events; blood draw
(laboratory testing); collection of boxes with sachets
of used study medication for compliance control. The
full planned visiting and examination schedule is provided
in Fig. 2.
Quality assurance
To assess high-quality conduct of the trial in accordance
with the protocol, all medical staff involved in this study
are certified in Good Clinical Practice (GCP). The phys-
iotherapists who perform the tests were trained and
certified in Lyon where the MFM scale has been estab-
lished and validated. To assess compliance of medication
intake, empty and full boxes with sachets are returned
by the patients at visits 4 and 5.
Allocation concealment is assured by an unblinded
pharmacist who has access to the randomisation list.
The investigator and the participants stay blinded until
the end of the study.
Fig. 2 Planned visiting and examination schedule *will be used as baseline values. Vital signs include: blood pressure, heart rate, weight at every
visit; height only at screening visit. Motor Function Measurement (MFM) scale, 6-min Walking Distance Test (6MWD), quantitative motor tests
(QMT), and screening will be used as baseline values. Full blood count: erythrocytes, reticulocytes, leucocytes, platelets, haemoglobin, haematocrit.
GOT, GPT, creatinine, electrolytes (Na+, K+, Ca2+), urea, creatine kinase (CK), glycosylated haemoglobin (HbA1c), cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides, calculated glomerular filtration rate (GFR). Oxidised DNA (8-hydroxy-2’-deoxyguanosine: 8OHDG),
carbonylated proteins (4-Hydroxynonenal (4-HNE)), mitochondrial proteins (citratsynthase, cytochrome C oxidase subunit 1, succinate dehydrogenase
subunit A), nitrotyrosine, cGMP. Woman of child-bearing potential. SIPP – Self-reported Impairments in Persons with late effects of Polio, IBM-FRS –
Inclusion Body Myositis Functional Rating Scale, WHOQOL-BREF – The WHO Quality of Life – BREF Questionnaire
Schmidt et al. Trials  (2017) 18:116 Page 4 of 9
Safety assessments
Adverse events are monitored throughout the study. At
every study visit, patients are asked about adverse
events. At visits 1, 3, 4 and 5, a physical examination will
be performed and the vital parameters will be measured.
The following safety parameters are checked: full blood
count; blood chemistry (transaminases, creatinine,
electrolytes, urea); marker of muscle necrosis (creatine
kinase concentration); serum markers of oxidative stress
(8-hydroxy-2’-deoxyguanosine (8OHDG), carbonylated
proteins); serum markers of nitrosative stress (nitrotyro-
sine, cGMP); all amino acids; glucose metabolism
marker (HbA1c); lipid metabolism markers (cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), triglycerides). If pathological changes independ-
ent of the known muscle disease should be detected, the
affected patients will be informed immediately and the
possibilities of further investigation or treatment of these
abnormalities according to current medical knowledge,
respectively, will be discussed.
Withdrawal of consent, protocol violations caused by
the patients (noncompliance), logistical reasons, inability
to attend study visits as defined in the protocol, abnor-
mal laboratory results and abnormal increase in blood
pressure as determined by the investigator can lead to
an early termination of the study. Patients with adverse
reactions which have occurred in context of the study
are followed up by the investigator up to 30 days after
the last visit. Serious adverse events will be reported
within 7 days (after being reported by the patient) to the
local national Ethics Committee. Female patients of
child-bearing age will be instructed to use a double-
barrier method of birth control and to immediately
inform the investigator if they become pregnant during
the study. The study drug is discontinued at the discre-
tion of the investigator.
Outcome measures
Primary outcome measure
Change of 6MWD from week 24 to week 48 under L-
citrulline therapy versus placebo Several tests have
been reported in the medical literature to assess
muscle strength and functional ability, to monitor the
progression of the disease, and to evaluate the results
of drug interventions and rehabilitation. Timed clin-
ical functional assessments include the 6-min Walking
Distance Test (6MWD) in meters which is helpful to
assess muscle function and fatigue in patients with
neuromuscular disorders [16, 17]. The 6MWD is a val-
idated tool to measure the distance that an individual
is able to walk over a total of 6 min on a hard, flat sur-
face. The goal for the individual is to walk as far as
possible in 6 min. The individual is allowed to self-
pace and rest as needed as they traverse back and
forth along a marked walkway.
Secondary outcome measures
Change of MFM scale total score The MFM scale, a
validated assessment tool to measure motor function in
both ambulant and nonambulant patients with neuro-
muscular disorders, was developed in France in 2005. It
includes 32 items that evaluate three dimensions of
motor performance, including specific motor functions,
such as transfers and standing posture (D1), proximal
and axial (D2) and distal (D3) and a total MFM score in-
volving all of the motor dimensions. The items are
scored and summed to comprise a total score where the
maximum represents normal motor function. The in-
struction manual, validation examinations and other
publications using the MFM scale can be downloaded at
the MFM scale website [18].
Change of quantitative muscle MRI (IDEAL-CPMG
with T2 and lipid quantitation and dynamic
31P-MR
spectroscopy) One of the advantages of muscle MRI
imaging methods is that the raw data can be stored and
direct comparisons from data at several time points are
possible. Visual and semiquantitative muscle MRI stud-
ies have been applied in inherited neuromuscular disor-
ders, including SMA, and have identified anatomical
abnormality, such as absent, aberrant, or accessory mus-
cles, changes in tissue composition, such as fatty infiltra-
tion or increased water content, and masses or mass-like
lesions [19, 20]. We use the IDEAL-CPMG sequence
allowing simultaneous T2 and lipid quantitation and dy-
namic Phospho-magnet resonance (31P-MR) spectros-
copy that quantifies the kinetics of phosphocreatine
(PCr), ATP and intracellular pH in lower leg muscles
during rest, exercise and recovery. As this sequence is
not tested previously in an age-correlated group of
people without neuromuscular disorders, up to 20 age-
and gender-correlated subjects will be examined add-
itionally at one time point.
In neuromuscular disorders, quantitative muscle MRI
(qMRI) detects disease progression more sensitively
compared to other clinical scores. Excellent reproduci-
bility of qMRI was demonstrated in healthy volunteers
as well as in patients [21, 22]. qMRI was more sensitive
than clinical evaluation and visual analysis of MRI scans
to detect disease progression [20, 23, 24].
Change of serum concentrations for markers of
muscle necrosis (creatine kinase), oxidative stress
(8OHDG, carbonylated proteins 4-Hydroxynonenal
(4-HNE)), nitrosative stress (nitrotyrosine, cGMP),
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and mitochondrial-related genes (Citratsynthase,
Cytochrome C oxidase subunit 1, Succinate dehydro-
genase subunit A) Our treatment aims at a stimulation
of NO concentrations measured by indirect markers
(nitrotyrosine, cGMP), an improvement of the muscular
energy situation (citratsynthase, cytochrome C oxidase
subunit 1, succinate dehydrogenase subunit A) with re-
duction of oxidative stress (8OHDG in urine, carbony-
lated proteins) and a slowing of muscle degeneration
(levels of creatine kinase, transaminases, alkaline
phosphatase).
Auxiliary outcome measures
Change of quantitative muscle test (QMT) of elbow
flexion, hand grip, knee extension and ankle exten-
sion using hand-held dynamometry (HHD) As the
distribution of muscle weakness in PPS patients varies
widely, a quantitative muscle testing, including different
muscles of the upper and lower limbs, provides probably
a more detailed insight into the distribution and evalu-
ation of muscle weakness in each patient.
Change of self-report questionnaires SIPP, IBM-FRS
and WHOQOL – BREF The Self-reported Impairments
in Persons with late effects of Polio (SIPP) is a new rat-
ing scale first published in 2013 and recently reevaluated
for test-retest reliability [25, 26]. The IBM-FRS (Inclu-
sion Body Myositis Functional Rating Scale) and the
WHOQOL (World Health Organisation – Quality of
Life) – BREF questionnaire are widely used and validated
scales to assess motor function especially in patients
with asymmetric neuromuscular conditions, such as in-
clusion body myositis, and/or quality of life regardless of
any underlying condition [27]. Our aim is to revalidate
test-retest reliability of these tests in our patient group
and to assess changes compared to other clinical and
subclinical outcome measures.
Randomisation scheme
The study aims to include 15 patients in each of two
treatment arms (placebo and verum). A randomisation
scheme called Big Stick Design [28] with a maximum
tolerated imbalance (MTI) between groups of two pa-
tients will be applied. The randomisation corresponds to
tossing a fair coin as long as the difference in group sizes
does not exceed the MTI. If the MTI is reached, a deter-
ministic allocation is performed so that the difference in
group sizes is reduced. For emergency breaking of the
group assignment, unblinding envelopes are provided.
These envelopes have a window in which only the run-
ning patient’s ID is visible and contain an unblinding
form that states the patient’s group assignment.
Sample size estimation
It is assumed that patients in the verum group will on
average have a 25% longer 6MWD after 24 weeks of
treatment with CIT compared to baseline. It is further
assumed that patients in the placebo group will on aver-
age have no improvement, but also no deterioration with
regard to the 6MWD over the 24 weeks of placebo treat-
ment. For sample size estimation, a data set from a study
of patients with Becker’s muscular dystrophy (BMD)
treated with the same CIT dose for 6 weeks was used
(performed at the University of Basel Children’s hospital,
publication in preparation). Patients (mean age 31 years)
were assigned to CIT treatment for the duration of
6 weeks and their 6 MWD was measured at baseline and
follow-up. Using a resampling method, each sample size
ni=1,…,41 = 10, …, 50 was evaluated by simulating 999
times ni patients with their 6MWD baseline and follow-
up values from a multivariate normal distribution. The
multivariate normal distribution was parameterised by
the mean 6MWD at baseline from the BMD data set,
the mean 6MWD at follow-up (mean baseline value aug-
mented by the expected relative increase θi=1,…41 = 0.1,
…, 0.5), and the variance-covariance matrix as estimated
from the BMD data set. The patients were randomised
in a 1:1 or 1:2 ratio to the placebo and the verum group,
respectively, in order to examine the effect of the ran-
domisation ratio on sample size. The resulting data set
was analysed with an analysis of covariance (ANCOVA)
with 6MWD follow-up measurement as response,
6MWD baseline measurement as adjusting covariate and
treatment group (placebo versus verum) as explanatory
variable of interest. Finally, it was tested whether there
was a difference between the placebo and verum groups.
For an expected mean increase in 6MWD of 25% in
the verum group, 28 subjects need to be recruited to ob-
tain 25 evaluable patients, assuming a dropout rate of
10% and when randomising patients 1:1 to placebo and
verum, respectively (Fig. 3). To further increase the sen-
sitivity, a similar 24-week run in observational period
will be performed in all patients before active or placebo
treatment. The latter should help within the placebo
group to separate natural history changes from placebo
effects during the treatment period.
Statistics
The full analysis set (FAS) consists of all patients who
are randomised and for whom a baseline measurement
of the primary endpoint is available. The intention-to-
treat (ITT) set is a subset of the FAS that consists of all
patients for whom there is a follow-up measurement of
the primary endpoint. According to the ITT principle,
each patient will be analysed according to the treatment
that they are randomly allocated to. The per-protocol
(PP) set is a subset of the ITT set that consists of all
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patients with complete follow-up measurements of the
primary endpoint. Each patient will be analysed accord-
ing to the treatment that they actually receive.
An ANCOVA will be used for the primary analysis.
The response variable is the 6MWD after the 24-week
treatment period (follow-up). The explanatory variables
are the 6MWD at the onset of the treatment period
(baseline) and the group (placebo versus verum). The
model estimates will be presented together with 95%
confidence intervals and p values with respect to the null
hypothesis that the corresponding estimate has a value
of 0. The analysis will be performed on the ITT set. The
analysis will be repeated on the PP set and compared to
the ITT analysis as a sensitivity analysis.
Following the analysis of the primary endpoint, the
secondary endpoints will be analysed as outlined above
for the primary endpoint.
Quality control
Monitoring of the study will be performed by an inde-
pendent person (KMS Monitoring, Zug). All inclusion
and exclusion criteria will be checked, whether the data
have been recorded correctly in the CRF, whether the
drug accountability is correct and whether any serious
adverse events (SAEs) have occurred during the study.
Ethical considerations
PPS is a serious progressive neuromuscular disease with
no therapy so far. Affected patients suffer from severe
impairment that justifies an attempt to improve this
condition using an almost side-effect-free treatment.
The participation in this study is voluntary. If the
patients do not want to participate, they will not experi-
ence any disadvantages concerning any further medical
treatment. The same applies if the patients withdraw the
consent at a later time point. They have this possibility
at any time. Possible withdrawal of consent from the
study can occur without giving any reason. In case of
withdrawal the data collected until this time point will
be used and the samples (blood) collected in the context
of the study will be destroyed. In case of withdrawal the
patient will undergo a final visit for a medical examin-
ation for his own safety.
A placebo group is necessary to demonstrate the effi-
cacy of the used medication (CIT) and to exclude a pos-
sible placebo effect.
There is a great potential that positive results of this
study could lead to other large multicenter trials. Fur-
thermore, if we can show an effect of CIT on muscle
function, this will be a major breakthrough and mean a
better symptomatic treatment of the muscle degener-
ation that occurs in PPS.
Discussion
The aim of this investigator-initiated, randomised,
placebo-controlled, double-blind, phase IIa trial is to
examine whether treatment with CIT has a beneficial ef-
fect on clinical muscle function and fatigue and on the
surrogate biomarkers that assess muscle ATP production
and mitochondrial function in PPS. If this turns out to
be the case, a cost-effective, symptomatic therapy with
CIT could be available for these patients.
As PPS is a very heterogeneous disease, all patients
will undergo a 24-week observational (untreated) period
to observe the natural history of the disease. For the pri-
mary endpoint the 6MWD was chosen, which implies
that all included patients are still ambulatory. As phys-
ical fatigue is one of the major and most limiting symp-
toms [3], the 6MWD seems to be the ideal endpoint to
observe positive effects on muscle function, and to
assess fatigue and endurance due to CIT intake. Further-
more, due to the asymmetric nature of the disorder the
6MWD seems to be optimal regardless of whether walk-
ing impairment is caused by the right or left proximal or
distal leg being affected.
The MFM is a scale used in neuromuscular diseases to
assess their severity and progression. It is used by phys-
iotherapists or rehabilitation physicians and is useful to
observe motor function changes in clinical trials [29].
The test includes 32 items including specific motor
functions such as transfers and standing (D1), proximal
and axial (D2) and distal (D3). The total MFM score in-
volves all the motor dimensions [18] and can, therefore,
Fig. 3 Randomisation placebo:verum 1:1. Association of sample size
(N) and the mean relative improvement of the verum group in the
6-min Walking Distance Test at follow-up (θ), assuming no improvement
in the placebo group, for a randomisation ratio of 1:1 into the placebo
and verum groups, respectively. Curves are smoothed for illustration
purposes only
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also detect motor function changes in body parts which
are not involved in walking and are not evaluated in the
6MWD.
In order to increase sensitivity and to detect subclin-
ical positive effects on muscle mass and muscle metabol-
ism, quantitative muscle MRI (qMRI) is performed. We
and others have demonstrated that qMRI is more sensi-
tive than clinical evaluation and visual analysis of MRI
scans and it also shows an excellent reproducibility [20,
21, 24]. qMRI is a powerful technique to evaluate neuro-
muscular and muscular disorders in a noninvasive way
for evaluation of disease progression and, furthermore, it
is a good biomarker in clinical trials [30]. Kinali et al.
showed a good correlation between muscle histology
and MRI changes in patients with DMD [31]. Further-
more, to investigate ATP in human muscle in vivo,
31P-MR spectroscopy is used (during rest, exercise
and recovery). With this method, the mitochondrial
function and the regeneration of ATP after muscle
exercise could be investigated.
Trial status
The trial started enrolment in June 2016 and is expected
to be completed by the end of August 2017.
Additional file
Additional file 1: Recommended items to address in a clinical trial
protocol and related documents. (PDF 57 kb)
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NO: Nitric oxide; NOS: Nitric oxide synthase; PCr: Phosphocreatine; PGC-
1α: Peroxisome proliferator-activated receptor-γ coactivator 1α; PPS: Post-
polio syndrome; qMRI: Quantitative magnetic resonance imaging; SIPP: Self-
reported Impairments in Persons with late effects of Polio rating scale;
WHOQOL: The World Health Organisation - Quality Of Life
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